Editorial
Rev Diabet Stud,
2005,
2(4):182-186 |
DOI 10.1900/RDS.2005.2.182 |
Imbalance in Th Cell Polarization and its Relevance in Type 1 Diabetes Mellitus
Charles Sia
Department of Immunology, United Biomedical Inc., 25 Davids Drive, Hauppage, New York 11788, USA, e-mail: csia@unitedbiomedical.com.
Keywords: type 1 diabetes, Th cell, polarization
Abstract
Functional polarization of T helper (Th) subsets of lymphocytes has been implicated in promoting or conferring risk to Type 1 diabetes mellitus (T1DM) development in human and diabetic animal models. It is assumed that an immoderate preponderance of type 1 immunity establishes the prerequisite for this development. Over the past years, various immune-intervention strategies have been tested to protect diabetic animals from developing overt diabetes. These protocols implicate a protective mechanism that is attributed to a change in the set of autoreactive Th cells from their Th1 to the Th2 phenotype. The studies were aimed at improving the effectiveness of Th2 cells to secrete the principal cytokines, IL-4 and IL-10, in order to mediate protection from diabetes in NOD mice. In contrast, some immune-modulation protocols utilizing non-specific reagents report that diabetes protection is apparently attributed to preferential survival of both Th1 and Th2 cells, rather than via a shift from their Th1 to Th2 phenotypes. Even though we know that excessive immune responses against self antigens are also controlled and terminated by regulatory T cells, this article focuses on the polarization of Th effector cells and discusses the controversial findings regarding the Th1/Th2 hypothesis to draw a conclusion on its relevance in T1DM from the existing knowledge.
Fulltext:
HTML
, PDF
(299KB)
This article has been cited by other articles:
|
Novel biomarkers in type 1 diabetes
Jin Y, She JX
Rev Diabet Stud 2012. 9(4):224-235
|
|
|
Chemokine (C-C motif) ligand 2 (CCL2) in sera of patients with type 1 diabetes and diabetic complications
Guan R, Purohit S, Wang H, Bode B, Reed JC, Steed RD, Anderson SW, Steed L, Hopkins D, Xia C, She JX
Plos One 2011. 6(4):e17822
|
|
|
Intramuscular delivery of a naked DNA plasmid encoding proinsulin and pancreatic regenerating III protein ameliorates type 1 diabetes mellitus
Hou WR, Xie SN, Wang HJ, Su YY, Lu JL, Li LL, Zhang SS, Xiang M
Pharmacol Res 2011. 63(4):320-327
|
|
|
Vitamin D and diabetes
Takiishi T, Gysemans C, Bouillon R, Mathieu C
Endocrinol Metab Clin North Am 2010. 39(2):419-446
|
|
|
Immunopathology of the human pancreas in type-I diabetes
Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK
Semin Immunopathol 2010. Apr 28, epub ahead of print
|
|
|
Immunomodulatory effect of fibres, probiotics and synbiotics in different life-stages
Romeo J, Nova E, Wärnberg J, Gomez-Martinez S, Ligia LE, Marcos A
Nutr Hosp 2010. 25(3):341-349
|
|
|
Strategies for diabetes and pathways of vitamin D
Tuorkey MJ, Abdul-Aziz KK
Diabetes Metab Syndr 2009. 4(2):101-110
|
|
|
The role of the CXCL10/CXCR3 system in type 1 diabetes
Shimada A, Oikawa Y, Yamada Y, Okubo Y, Narumi S
Rev Diabet Stud 2009. 6(2):81-84
|
|
|
SUMO conjugation contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf transactivation of IL-4
Leavenworth JW, Ma X, Mo YY, Pauza ME
J Immunol 2009. 183(2):1110-1119
|
|
|
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes
Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R
J Immunol 2009. 183(2):993-1004
|
|
|
Genetic deficiency of Itgb2 or ItgaL prevents autoimmune diabetes through distinctly different mechanisms in NOD/LtJ mice
Glawe JD, Patrick DR, Huang M, Sharp CD, Barlow SC, Kevil CG
Diabetes 2009. 58(6):1292-1301
|
|
|
Analysis of islet inflammation in human type 1 diabetes
Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG
Clin Exp Immunol 2009. 155(2):173-181
|
|
|
Gene therapy in type 1 diabetes
Bagley J, Paez-Cortez J, Tian C, Iacomini J
Crit Rev Immunol 2008. 28(4):301-324
|
|
|
The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes
Mabley JG, Pacher P, Murthy KG, Williams W, Southan GJ, Salzman AL, Szabo C
J Endocrinol 2008. 198(3):581-589
|
|
|
Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production
Bitan M, Weiss L, Zeira M, Reich S, Pappo O, Vlodavsky I, Slavin S
Diabetes Metab Res Rev 2008. 24(5):413-421
|
|
|
Feeding our immune system: impact on metabolism
Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, Grangette C
Clin Dev Immunol 2008. 2008:639803
|
|
|
Improved efficacy of P277 fused to heat shock protein 65 of Mycobacterium tuberculosis against diabetes in nonobese diabetic mice
Zhu A, Lu Y, Jin L, Wu J, Li T, Liu J
Sheng Wu Gong Cheng Xue Bao (Chinese Journal of Biotechnology) 2008. 24(4):640-645
|
|
|
Review of the literature: integrating psychoneuroimmunology into pediatric chronic illness interventions
Nassau JH, Tien K, Fritz GK
J Pediatr Psychol 2008. 33(2):195-207
|
|
|
IL-10 gene modified dendritic cells inhibit T helper type 1-mediated alloimmune responses and promote immunological tolerance in diabetes
Zhu H, Qiu W, Lei P, Zhou W, Wen X, He F, Li L, Dai H, Shen G, Gong F
Cell Mol Immunol 2008. 5(1):41-46
|
|
|
Effect of Displaying P277 Peptide on Surface of L-asparaginase on Its Antigenicity and Efficacy of Autoimmune Diabetes Prevention in NOD Mice
Zhu AH, Liu WT, Long J, Wu J, Liu JJ, Li TM
Chinese Journal of Biochemistry and Molecular Biology 2007. 23(9):730-737
|
|
|
Expression and purification of peptide P277 and its primary pharmacology
Zhu AH, Liu WT, Lu Y, Jin L, Wang Y, LIU JJ
J Yangzhou Univ 2007. 28(4):13-17
|
|
|